Evanguelos Xylinas1, Luis A Kluth1, Yair Lotan2, Siamak Daneshmand3, Malte Rieken1, Pierre I Karakiewicz4, Shahrokh F Shariat5. 1. Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY. 2. Department of Urology, University of Texas Southwestern Medical Center, Dallas, TX. 3. USC Institute of Urology, Norris Comprehensive Cancer Center, Los Angeles, CA. 4. Department of Urology, University of Montreal Health Center, Montreal, Canada. 5. Department of Urology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Division of Medical Oncology, Weill Medical College of Cornell University, New York-Presbyterian Hospital, New York, NY; Department of Urology, Medical University of Vienna, Vienna, Austria. Electronic address: sfshariat@gmail.com.
Abstract
OBJECTIVES: Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB. MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis. RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper. CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.
OBJECTIVES:Urothelial carcinoma of the bladder (UCB) is a highly heterogeneous malignancy that causes significant morbidity and mortality. Standard pathologic features (stage, grade, and nodal status) are insufficient to predict accurately a patient's outcome. Biomarkers could help clinicians provide individualized prognostications and allow risk-stratified clinical decision making regarding surgical and medical treatment. This review summarizes the existing tissue- and blood-based biomarkers in UCB. MATERIAL AND METHODS: A PubMed/Medline search was conducted to identify original articles regarding molecular biomarkers and UCB. Searches were limited to papers published in English. Keywords included urothelial carcinoma, bladder cancer, transitional cell, biomarker, marker, staining, cystectomy, recurrence or progression, survival, prediction, and prognosis. RESULTS: The articles with the highest level of evidence were selected and reviewed, with the consensus of all the authors of this paper. CONCLUSIONS: There is no doubt that a panel of biomarkers would eventually improve our clinical decision making regarding treatment and follow-up. However, to date, no biomarker panel is yet validated for daily clinical practice.
Authors: Laura-Maria Krabbe; Vitaly Margulis; Andres Jan Schrader; Shahrokh F Shariat; Kilian M Gust; Martin Boegemann Journal: World J Urol Date: 2018-06-08 Impact factor: 4.226
Authors: Ricardo L Favaretto; Stênio C Zequi; Renato A R Oliveira; Thiago Santana; Walter H Costa; Isabela W Cunha; Gustavo C Guimarães Journal: Int Braz J Urol Date: 2018 Jan-Feb Impact factor: 1.541
Authors: Friedrich-Carl von Rundstedt; Kimal Rajapakshe; Jing Ma; James M Arnold; Jie Gohlke; Vasanta Putluri; Rashmi Krishnapuram; D Badrajee Piyarathna; Yair Lotan; Daniel Gödde; Stephan Roth; Stephan Störkel; Jonathan M Levitt; George Michailidis; Arun Sreekumar; Seth P Lerner; Cristian Coarfa; Nagireddy Putluri Journal: J Urol Date: 2016-01-21 Impact factor: 7.450